Pulmonary Arterial Hypertension

Older patients with pulmonary arterial hypertension may have lower pulmonary artery compliance and worse right ventricular performance compared with their younger counterparts.

Balloon pulmonary angioplasty and pulmonary vasodilators were both found to improve functional and hemodynamic outcomes in patients with inoperable chronic thromboembolic pulmonary hypertension.

Risk stratification for survival and time to clinical worsening in pulmonary arterial hypertension based on 2015 ESC/ERS guidelines was confirmed only in patients without comorbidities.

Overall survival in congenital heart disease-associated pulmonary hypertension has been shown to be significantly better than in idiopathic pulmonary arterial hypertension.

Balloon pulmonary angioplasty can improve quality of life in patients with chronic thromboembolic pulmonary hypertension mainly by improving “usual activities.”

Bayesian machine learning algorithms can improve discrimination of risk stratification in pulmonary arterial hypertension.

With close monitoring, the use of oral add-on treatment with selexipag in children with pulmonary arterial hypertension was safe and well tolerated.

In patients with pulmonary arterial hypertension, renal function is important for determining mortality risk and improves stratification of risk.

In patients with pulmonary arterial hypertension, high levels of platelet endothelial cell adhesion molecule 1 (PECAM-1) are associated with less improvement in 6-minute walk distance and may also be predictive of response to treprostinil.

Patients with precapillary pulmonary hypertension and pulmonary vascular resistance who do meet the definition of PAH may have functional limitations and may benefit from therapy.